norketotifen

Norketotifen is a biologically active demethylated metabolite of ketotifen, developed as a pharmaceutical drug for its antihistaminic and anti-inflammatory properties. It acts as an antagonist at histamine H1 and H4 receptors, serving as both an antihistamine and mast cell stabilizer. Unlike ketotifen, norketotifen lacks sedative effects, allowing for higher dosing without sedation as a limiting factor. It also exhibits dose-dependent inhibition of the pro-inflammatory cytokine TNF-α and inhibits eosinophil accumulation. Norketotifen is under clinical development for conditions such as allergic rhinitis, uncomplicated influenza, flu-like viral infections, chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), and atopic dermatitis. The compound was originally patented by Sandoz Pharmaceuticals (now part of Novartis) but is currently being developed by Emergo Therapeutics. Norketotifen is notable for its lack of sedative effects compared to ketotifen and has been shown to be effective in preclinical models for both oral and topical administration. Its unique dual antagonism at histamine H1/H4 receptors may offer advantages over traditional antihistamines.

Other names

NK